PRP vs polynucleotides— which supports hydration better?
Both platelet-rich plasma (PRP) and polynucleotides are being explored to improve vulvo-vaginal moisture and comfort in genitourinary syndrome of menopause (GSM). Early studies suggest each may help some people, but evidence is small and mixed; neither outperforms guideline first lines (moisturisers/lubricants and, where needed, local vaginal oestrogen or DHEA). If used, they’re add-ons after foundations, with clear discussion of benefits, risks and costs. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
PRP vs polynucleotides— which supports hydration better? Think of GSM as a biology problem (low oestrogen thins tissue, raises pH and reduces lactobacilli) plus a mechanics problem (friction, micro-tears, stinging). PRP and polynucleotides try to influence the mechanical side by improving tissue quality and slip, while guideline therapies like local vaginal oestrogen or vaginal DHEA directly repair the low-oestrogen biology. On current evidence, neither PRP nor polynucleotides has proven superiority for “hydration”; both are best considered adjuncts after foundations.
How PRP works (in theory). PRP is prepared from your own blood, concentrating platelets and growth factors (e.g., PDGF, TGF-β, VEGF). Small aliquots are injected into the vestibule and/or vaginal wall. The aim is to nudge a local repair response—better blood flow, matrix turnover and mucosal comfort—so everyday movement feels less “sandpapery” and initial penetration stings less. Because it’s autologous, allergy risk is low, but outcomes depend on technique, platelet yield and placement.
How polynucleotides work (in theory). Polynucleotides (highly purified DNA fragments, often salmon-derived) are biostimulatory injectables used in dermatology to improve extracellular matrix quality and water retention. In intimate skin/mucosa, they are proposed to bind water, reduce oxidative stress and encourage fibroblast activity—translating to a dewier, more elastic feel. They are not fillers; they don’t “bulk” the area like hyaluronic-acid fillers do. Potential sensitivity exists for fish-derived products; sourcing and purification vary by manufacturer (® belongs to its owner).
So which is “better” for hydration? Evidence is insufficient to crown a winner. Small studies and case series suggest both can help selected patients, particularly when the sore spot is the vestibule/posterior fourchette and lubricants alone haven’t prevented micro-tears. However, study sizes are small, techniques heterogeneous, comparators weak, and follow-up short. By contrast, guideline-backed local oestrogen consistently improves dryness, pH and dyspareunia across formats. In practice, we prioritise moisturiser + compatible lubricant, add local therapy if needed, and consider PRP or polynucleotides only if symptoms remain intrusive or hormones are unsuitable/declined.
Choosing between them—practical considerations. If you prefer an autologous option, PRP avoids exogenous compounds but depends on your platelet function. If you have fish allergy or prefer to avoid animal-derived products, polynucleotides may be unsuitable; check the product source. Placement matters more than brand: if your pain is entrance-focused, targeting the vestibule is crucial whatever you choose. Plan review points (6–12 weeks) and avoid assuming equivalence—your response may differ.
Day-to-day comfort still hinges on basics. Keep washing gentle (lukewarm water; bland emollient as a soap substitute), wear breathable cotton underwear, change out of sweaty kit promptly, schedule a vaginal moisturiser (many prefer hyaluronic-acid gels) 2–4 times weekly, and use a personal lubricant early and generously for higher-friction moments. If pelvic floor guarding developed after painful sex, pelvic health physiotherapy (and, if needed, graded dilators) often does more for comfort than any injection.
For a plain-English overview of how treatments are sequenced and practical planning such as packages and reviews (treatment prices), see our clinic pages.
Clinical Context
Who may consider PRP or polynucleotides? People with GSM whose main problem is entrance-focused burning or “paper-cut” micro-tears despite a solid moisturiser + lubricant routine, and who cannot use—or prefer not to use—local vaginal hormones; or those improved on local therapy but still limited by friction. Expect gradual change over weeks and plan a review at 6–12 weeks.
Who should avoid or delay? Anyone with active thrush/BV/UTI, malodorous discharge, fever, severe pelvic pain, visible haematuria, or new post-menopausal bleeding; people with bleeding disorders/anticoagulation (for PRP), or fish allergy/sensitivity to product components (for polynucleotides). Recent pelvic surgery without clearance also warrants deferral. Address pelvic floor over-activity first, as injectables cannot relax muscles.
Alternatives & next steps. Reinforce basics (gentle care, breathable underwear), optimise local oestrogen or vaginal DHEA placement if acceptable, and add psychosexual support if apprehension is sustaining pain. If choosing injectables, consent should cover technique, expected course, costs, and what to do if progress stalls (reassess diagnosis and product placement before repeating sessions). Educational only. Results vary. Not a cure.
Evidence-Based Approaches
Guideline first lines (UK): The NHS provides symptom overviews and self-care for vaginal dryness. The NICE Menopause Guideline (NG23) recommends vaginal moisturisers and lubricants and considering low-dose local vaginal oestrogen when GSM affects quality of life; local therapy can be used with or without HRT.
Comparators with stronger evidence: Cochrane reviews consistently show that local vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo across creams, pessaries/tablets and rings—providing a benchmark for symptom relief (Cochrane Library).
PRP data (emerging): Small trials and case series suggest PRP may help selected patients with GSM-related dryness/dyspareunia; heterogeneity in preparation, dosing and follow-up limits certainty. Representative peer-reviewed summaries and pilot studies can be found via PubMed.
Polynucleotides data (emerging): Published evidence in vulvo-vaginal applications is limited and heterogeneous, extrapolated partly from dermatology literature on hydration and matrix quality; intimate-area trials remain small. Overviews and early studies are indexed on PubMed. Product selection should consider UK device/medicine status and purification source. ® belongs to its owner.
Prescribing/product detail for local therapies: UK information and cautions for vaginal oestrogens and prasterone (DHEA) appear in the British National Formulary (BNF). These remain the preferred step when non-hormonal measures are insufficient.
Applying the evidence: Use a stepped plan: moisturiser + compatible lubricant → add local therapy if needed → consider PRP or polynucleotides only as adjuncts when guideline-led measures are insufficient or unsuitable, with transparent counselling on benefits, limits, costs and maintenance.